NephroGenex Company Profile (NASDAQ:NRX)

About NephroGenex

NephroGenex logoNephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NRX
  • CUSIP:
Key Metrics:
  • Previous Close: $0.14
  • 50 Day Moving Average: $0.4029
  • 200 Day Moving Average: $1.1666
  • 52-Week Range: $0.10 - $8.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.08
  • P/E Growth: 0.0000
  • Market Cap: $N/A
Additional Links:
Companies Related to NephroGenex:

Analyst Ratings

Consensus Ratings for NephroGenex (NASDAQ:NRX) (?)
Ratings Breakdown: 2 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for NephroGenex (NASDAQ:NRX)
DateFirmActionRatingPrice TargetDetails
4/15/2016Rodman & RenshawReiterated RatingNeutralView Rating Details
4/8/2016HC WainwrightDowngradeBuy -> NeutralView Rating Details
8/17/2015MLV & Co.Reiterated RatingBuy$20.00View Rating Details
12/31/2014AegisReiterated RatingBuy$15.00View Rating Details
(Data available from 10/26/2014 forward)


Earnings History for NephroGenex (NASDAQ:NRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/11/2015Q315($0.65)($0.53)ViewListenView Earnings Details
8/12/2015Q215($0.56)($0.72)ViewListenView Earnings Details
5/13/2015Q115($0.62)($0.58)ViewN/AView Earnings Details
3/24/2015Q414($0.58)($0.60)ViewN/AView Earnings Details
11/12/2014Q314($0.46)($0.50)ViewN/AView Earnings Details
8/11/2014($0.24)($0.61)ViewN/AView Earnings Details
5/14/2014Q114($0.37)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NephroGenex (NASDAQ:NRX)
Current Year EPS Consensus Estimate: $-0.3000 EPS
Next Year EPS Consensus Estimate: $-1.7100 EPS


Dividend History for NephroGenex (NASDAQ:NRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for NephroGenex (NASDAQ:NRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/6/2015Ventures V L.P. RhoMajor ShareholderSell273,860$10.58$2,897,438.80View SEC Filing  
11/25/2014Bob PetersonVPBuy2,000$4.20$8,400.00View SEC Filing  
2/14/2014Robert R SeltzerDirectorBuy790,000$12.00$9,480,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for NephroGenex (NASDAQ:NRX)
DateHeadline logoNaturex SA :NRX-FR: Earnings Analysis: Q4, 2015 By the Numbers : August 9, 2016 (NASDAQ:NRX) - August 9 at 9:43 AM logoNephroGenex, Inc. (NRX) Updated Price Targets - FTSE News (NASDAQ:NRX) - July 26 at 9:44 AM logoNephroGenex, Inc. (NRX) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:NRX) - July 17 at 5:56 PM logoBrokers Issue Average Price Target Of 17.50 On NephroGenex, Inc. (NRX) - Fiscal Standard (NASDAQ:NRX) - July 9 at 9:45 AM logoRecently Issued Stock Ratings For NephroGenex, Inc. (NRX) - Fiscal Standard (NASDAQ:NRX) - July 1 at 6:31 PM logoNext Weeks Broker Price Targets For NephroGenex, Inc. (NRX) - Fiscal Standard (NASDAQ:NRX) - June 28 at 11:21 AM logoNew Broker Ratings For NephroGenex, Inc. (NRX) - FTSE News (NASDAQ:NRX) - June 25 at 10:14 AM
News IconNext Weeks Broker Price Targets For NephroGenex, Inc. (NRX) - Share Trading News (NASDAQ:NRX) - May 30 at 10:02 PM logoNephroGenex, Inc. (NASDAQ:NRX) Closes At $0.1401 - (NASDAQ:NRX) - May 27 at 2:37 PM logo3 Companies Filed For Chapter 11 Bankruptcy Today (NASDAQ:NRX) - May 2 at 2:37 PM logoNephroGenex Files For Bankruptcy Protection Under Chapter 11 (NASDAQ:NRX) - May 2 at 9:43 AM logoNephroGenex, Inc. Commences Voluntary Chapter 11 Proceeding; Seeks To Initiate Sale Process Under Section 363 (NASDAQ:NRX) - May 2 at 8:20 AM logoResearch Triangle area's biotech sector in steep bear market (NASDAQ:NRX) - April 26 at 3:00 PM logoHow NephroGenex went from darling to disaster (NASDAQ:NRX) - April 14 at 4:30 PM logoNephroGenex downgraded by H.C. Wainwright (NASDAQ:NRX) - April 8 at 7:10 AM logoNATUREX - FY 2015 Results (NASDAQ:NRX) - March 31 at 2:46 AM
News IconNephroGenex restructuring; INC forecasts $1B in revenue; PRA reports major growth (NASDAQ:NRX) - February 26 at 1:40 PM logoNEPHROGENEX, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Costs Associated with Exit or D (NASDAQ:NRX) - February 24 at 4:31 PM logoHere's Why NephroGenex Plunged 40% On Wednesday (NASDAQ:NRX) - February 24 at 3:16 PM logoNephroGenex stock tumbles after announcement to halt trial over consideration of reverse merger (NASDAQ:NRX) - February 24 at 11:24 AM logoNephroGenex Provides Corporate Update (NASDAQ:NRX) - February 24 at 9:20 AM logoQ4 2015 NephroGenex Inc Earnings Release - After Market Close (NASDAQ:NRX) - February 24 at 7:07 AM logoNephroGenex to Host Conference Call and Webcast on Fourth Quarter and Full Year 2015 Financial Results on Thursday, February 25, 2016 (NASDAQ:NRX) - February 16 at 8:00 AM
News IconLatest Analysts Reports On NephroGenex, Inc. (NRX) - Risers & Fallers (NASDAQ:NRX) - February 7 at 2:32 PM
News IconDaily Watch List: NephroGenex (NASDAQ:NRX), Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP), Crescent Point ... - Property Mentor (NASDAQ:NRX) - February 4 at 3:00 PM
News IconNephroGenex, Inc. (NASDAQ:NRX) Short Interest Update - The Daily Rover (NASDAQ:NRX) - January 29 at 2:23 PM logoNephroGenex to Present at the 18th Annual BIO CEO & Investor Conference - Business Wire (press release) (NASDAQ:NRX) - January 27 at 1:43 PM logoNephroGenex to Present at the 18th Annual BIO CEO & Investor Conference (NASDAQ:NRX) - January 27 at 8:26 AM
News IconNephroGenex, Inc. Analyst Rating Update - WallStreet Prudent (NASDAQ:NRX) - January 26 at 2:19 PM
News IconCompany Shares of NephroGenex, Inc. (NASDAQ:NRX) Drops by -9.82% - Market Briefing (NASDAQ:NRX) - January 25 at 1:36 PM
News IconNephroGenex Receives a Buy from Rodman & Renshaw - (NASDAQ:NRX) - January 24 at 12:45 PM
News Icon3 Stocks Jumping on Abnormally High Volume: Cardica, Inc. (CRDC), NephroGenex Inc (NRX), Synergy Resources ... - Street Register (NASDAQ:NRX) - January 24 at 12:45 PM logoAMGN Gets FDA Nod, Data Awaits RGLS In Feb, FORWARD Puts ALKS On The Back Foot - Nasdaq (NASDAQ:NRX) - January 22 at 8:38 PM logoPre-Open Stock Movers 01/22: (NRX) (EGHT) (CHK) Higher; (CSII) (LGCY) (DGII) Lower (more...) - (NASDAQ:NRX) - January 22 at 8:38 PM logoNephroGenex (NRX) Reports IDSMB Recommendation to Continue Oral Pyridorin Phase 3 as Planned (NASDAQ:NRX) - January 22 at 8:38 PM logoNephroGenex (NRX) Reports IDSMB Recommendation to Continue Oral Pyridorin ... - (NASDAQ:NRX) - January 21 at 8:49 PM logoNephroGenex Announces Independent DSMB Recommendation to Continue Phase 3 Study of Oral Pyridorin in Diabetic Nephropathy Without Modification (NASDAQ:NRX) - January 21 at 4:39 PM logo4:11 pm NephroGenex announces independent DSMB recommendation to continue Phase 3 study of oral Pyridorin in diabetic nephropathy without modification (NASDAQ:NRX) - January 21 at 4:11 PM logoNEPHROGENEX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:NRX) - January 7 at 4:03 PM logoNephroGenex to Participate in Two Healthcare Conferences in January (NASDAQ:NRX) - January 6 at 8:00 AM logoNephroGenex Announces Formation of Scientific Advisory Board (NASDAQ:NRX) - January 5 at 8:00 AM logoRaleigh drug developer sees shares soar on good news from FDA (NASDAQ:NRX) - December 14 at 5:40 PM logoWhy Are Investors Piling Into These Stocks? (NASDAQ:NRX) - December 14 at 3:58 PM logoThanks, FDA: NephroGenex Investors Rejoice After New Clearance (NASDAQ:NRX) - December 14 at 12:52 PM logoNephroGenex (NRX) Stock Soars After FDA Approves Clinical Trials for Kidney Treatment (NASDAQ:NRX) - December 14 at 11:29 AM logoNephroGenex Announces FDA Clearance of IND Application for Clinical Study of Intravenous Pyridorin in the Treatment of Acute Kidney Injury (NASDAQ:NRX) - December 14 at 8:00 AM logoNEPHROGENEX, INC. Financials (NASDAQ:NRX) - December 8 at 1:18 PM logoNEPHROGENEX, INC. Files SEC form 8-K, Financial Statements and Exhibits (NASDAQ:NRX) - November 13 at 7:14 AM logoNephroGenex Reports Third Quarter 2015 Financial Results (NASDAQ:NRX) - November 11 at 4:16 PM


NephroGenex (NASDAQ:NRX) Chart for Wednesday, October, 26, 2016

Last Updated on 10/26/2016 by Staff